Abstract 2051P
Background
The implementation process, characteristics and objectives of the companion program have been previously reported. Briefly, the program consisted of a web containing an e-PRO questionnaire platform with real time monitoring for early symptom detection and intervention, a communication channel for resolving doubts and educational resources on diagnosis, treatment and adverse events. We aimed to determine the impact of the program in terms of reduction of emergency visits (ERV) and non-planned inpatient admissions (NIA).
Methods
Case-control analysis of patients with gastrointestinal cancer receiving systemic treatment (chemotherapy, immunotherapy, targeted therapy or combinations) at Oncosalud between June 2021 and July 2022. Patients were divided into two cohorts according to enrollment into the companion. Incidence rate (IR), IR ratios (IRR) and 95% confidence intervals were calculated. Time to first ERV and NIA curves since enrollment were constructed using the Kaplan Meier method and log rank test.
Results
In total, 199 patients were included, 97 enrolled into the program (cases). Mean age was 61.4 (±13.2), 50.3% were women and 94% were in ECOG 1-2. Chemotherapy was the most common treatment (88.4%). There were no differences in these characteristics between groups. The mean follow time was of 8.3 and 6.7 months, for cases and controls respectively. A statistically significant reduction in incidence rates was observed for both outcomes. ERV IR was 20.3 ERV per month in controls (95% CI:17.0-24.0) vs 15.1 ERV per month in cases (95%CI:12.6-18.0) which translated into a 25% decrease in ERV (IRR: 0.75 (95%CI:0.58-0.96; p=0.02)). NIA IR was 9.2 NIA per month in controls (95%CI:7.0-11.8) vs 5.9 NIA per month in cases (95%CI:4.4-7.8) which translated into a 35% decrease in NIA (IRR: 0.65 (95%CI:0.44-0.96; p=0.02)). There were no differences in time to first event for both outcomes.
Conclusions
The results demonstrate that e-PRO monitoring within a comprehensive companion program for cancer patients undergoing systemic treatment achieves clinical benefits as it reduces ERV and NIA. Its potential impact on outcomes and costs is being evaluated and will be reported.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncosalud.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06